Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma
  1. Home
  2. Publications
  3. Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

Authors:
  • LPLeah M Prentice
    Leah M Prentice
  • CKChristian Klausen
    Christian Klausen
  • SKSteve Kalloger
    Steve Kalloger
  • MKMartin Köbel
    Martin Köbel
  • SMSteven McKinney
    Steven McKinney
  • JSJennifer L Santos
    Jennifer L Santos
  • CKChallayne Kenney
    Challayne Kenney
  • EMErika Mehl
    Erika Mehl
  • CGC B Gilks
    C B Gilks
  • PLPeter Leung
    Peter Leung
  • KSKen Swenerton
    Ken Swenerton
  • DHDavid G Huntsman
    David G Huntsman

Open Access
Publisher website
Google Scholar
    • other
    • DOI:10.14288/1.0220719
Abstract
No abstract available
Keywords
  • GPR54
  • KISSPEPTIN
  • FAVOURABLE PROGNOSIS
  • SPECIFIC SURVIVAL
  • OVARIAN CARCINOMA SUBTYPE
Cited by 1 article
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.